Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD.

× No keyword cloud information.

5 in total

1. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease.

Authors: Margaret L Macmillan; Daniel Couriel; Daniel J Weisdorf; Gisela Schwab; Nancy Havrilla; Thomas R Fleming; Saling Huang; Lorin Roskos; Shimon Slavin; Richard K Shadduck; John Dipersio; Mary Territo; Steve Pavletic; Charles Linker; Helen E Heslop; H Joachim Deeg; Bruce R Blazar
Journal: Blood Date: 2006-11-16 Impact factor: 22.113

2. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.

Authors: Gérard Socié; Stéphane Vigouroux; Ibrahim Yakoub-Agha; Jacques-Olivier Bay; Sabine Fürst; Karin Bilger; Felipe Suarez; Mauricette Michallet; Dominique Bron; Philippe Gard; Zakaria Medeghri; Philippe Lehert; Chinglin Lai; Tim Corn; Jean-Paul Vernant
Journal: Blood Date: 2016-11-29 Impact factor: 22.113

Review 3. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Authors: Paul J Martin; J Douglas Rizzo; John R Wingard; Karen Ballen; Peter T Curtin; Corey Cutler; Mark R Litzow; Yago Nieto; Bipin N Savani; Jeffrey R Schriber; Paul J Shaughnessy; Donna A Wall; Paul A Carpenter
Journal: Biol Blood Marrow Transplant Date: 2012-04-14 Impact factor: 5.742

Review 4. How I treat refractory acute GVHD.

Authors: H Joachim Deeg
Journal: Blood Date: 2007-01-18 Impact factor: 22.113

Review 5. Graft-versus-host disease.

Authors: James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal: Lancet Date: 2009-03-11 Impact factor: 79.321

5 in total

7 in total

Review 1. Antibodies to watch in 2021.

Authors: Hélène Kaplon; Janice M Reichert
Journal: MAbs Date: 2021 Jan-Dec Impact factor: 5.857

Review 2. Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape.

Authors: Hildegard T Greinix; Francis Ayuk; Robert Zeiser
Journal: Leukemia Date: 2022-09-24 Impact factor: 12.883

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD.

1. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease.

2. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.

Review 3. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Review 4. How I treat refractory acute GVHD.

Review 5. Graft-versus-host disease.

Review 1. Antibodies to watch in 2021.

Review 2. Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape.

3. The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease.

Review 4. Established and Emerging Treatments of Skin GvHD.

5. Prediction of outcomes after second-line treatment for acute graft-versus-host disease.

Review 6. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.

Review 7. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease.